A single ascending dose (SAD) and multiple ascending dose Phase 1 clinical trial of KPL-387 in healthy volunteers.
Latest Information Update: 07 Mar 2025
At a glance
- Drugs KPL 387 (Primary)
- Indications Pericarditis
- Focus Adverse reactions
Most Recent Events
- 07 Mar 2025 New trial record
- 25 Feb 2025 According to a Kiniksa Pharmaceuticals media release, topline data from the SAD portion of the Phase 1 trial support potential monthly SC dosing in recurrent pericarditis.